Guerbet will celebrate its 100th anniversary at the ECR in Vienna from 4 to 8 March by unveiling a new centennial visual identity and providing the most recent updates on its macrocyclic gadolinium-based contrast agent Elucirem.
Elucirem (gadopiclenol) has been approved by the European Commission for use in adults and in children from birth for contrast-enhanced MRI to improve detection and visualization of pathologies with disruption of the blood-brain barrier and/or abnormal vascularity of the brain, spine, and associated tissues of the central nervous system as well as the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
The firm added that Elucirem requires half the conventional gadolinium dose as existing nonspecific contrast agents, thus reducing gadolinium exposure for patients.
Guerbet also said that its booth will host the French Pavilion at ECR 2026 under the aegis of the French Healthcare initiative. Additionally, it will have a dedicated patient case space to highlight the critical role of real-world evidence in radiology practice.
